This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (12) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Beglinger, L. J. Articles by Mohs, R. C. Search for Related Content PubMed PubMed Citation Articles by Beglinger, L. J. Articles by Mohs, R. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Neuropsychological Test Performance in Healthy Volunteers Before and After Donepezil Administration

Department of Neurology, Indiana University School of Medicine

Brenda L. Gaydos

Eli Lilly and Company, Indianapolis, IN, USA

David A. Kareken

Department of Neurology, Indiana University School of Medicine

Oranee Tangphao-Daniels

Eli Lilly and Company, Indianapolis, IN, USA daniels_oranee_t{at}lilly.com

Eric R. Siemers

Eli Lilly and Company, Indianapolis, IN, USA

Richard C. Mohs

Eli Lilly and Company, Indianapolis, IN, USA

Participants in early Phase I clinical trials for drugs designed to enhance cognition are typically healthy volunteers. If improvement can be detected with a battery of cognitive tests in healthy volunteers, such a battery could be a pharmacodynamic marker in the future development of the compound for treatment of cognitive disorders. In the present exploratory study, a battery of neuropsychological (NP) tests was used to determine if changes in cognition from a pharmacological intervention could be detected in healthy volunteers. A drug with known cognitive-enhancing effects in Alzheimer’s disease, donepezil, was compared with placebo and no treatment arms. Carry-over effects of repeated test administration were also assessed. In this double-blind study, 27 healthy adults were randomized into one of three arms (eight donepezil, nine placebo and 10 no treatment) and completed 14 days of donepezil (5 mg q.h.s.) or placebo (q.h.s.). A battery of NP tests was administered on days 0, 7, 14 (randomization), 21, 28 (end of treatment) and 42 (washout). There were no differences in performance between the placebo and the no treatment arms. However, on day 21, subjects in the donepezil group performed slightly but significantly worse on some tests of speed, attention and memory (p < 0.05) compared to the pooled control group (placebo and no treatment arms). No improvement in performance was present while on donepezil at days 21 or 28. While the results are counter to expectations, some tests in the battery did detect a cognitive change (transient mild worsening during drug administration) in healthy volunteers.

Key Words: clinical trials • cognition • donepezil • learning • memory • Phase I

Journal of Psychopharmacology, Vol. 18, No. 1, 102-108 (2004)
DOI: 10.1177/0269881104040248


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?